Impact Therapeutics expects H1 loss to narrow to RMB 81.7 million-RMB 99.9 million

• Impact Therapeutics guided for revenue of RMB 94.7-115.7 million for the six months ended June 30, 2026, up 276%-359%.
• Loss for the period seen at RMB 81.7-99.9 million, narrowing 22%-37% from RMB 128.7 million a year earlier.
• Higher sales tied to faster commercialization of senaparib following early-2026 inclusion in China’s National Reimbursement Drug List.
• Licensing revenue booked from a milestone payment under its Eikon collaboration as IMP1734 advanced into Phase II trials.
• Loss also reduced by lower interest from redemption liabilities on ordinary shares following a one-off termination of those liabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260811-12279726), on August 11, 2026, and is solely responsible for the information contained therein.